|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Magnesium sulfate and fetal neuroprotection: overview of clinical evidence显示文摘Antenatal administration of magnesium sulfate is an important part of the neuroprotective strategy for preterm infants. Strong evidence from five randomized controlled trials and five meta-analyses has demonstrated that magnesium sulfate, when administered before preterm delivery, significantly reduces the risk of cerebral palsy at two years. Through secondary analyses of randomized controlled trials and other original clinical studies, this state-of-the-art review highlights the absence of serious adverse effects in both pregnant women and neonates, as well as the impact of maternal body mass index and preeclamptic status on the maternal and neonatal magnesium levels, which could influence the magnitude of the neuroprotective effect. Although antenatal magnesium sulfate is a cost-effective strategy, some practice surveys have demonstrated that the use of magnesium sulfate is not sufficient and that its use is heterogeneous, differing among different maternity wards. Since 2010, an increasing number of obstetrical societies have recommended its use to improve the neurological outcomes of preterm infants, especially the International Federation of Gynecology and Obstetrics and World Health Organization in 2015, and France in 2017. Considering the neuroprotective impact of magnesium sulfate when administered before delivery, postnatal administration should be considered, and its effects should be assessed using randomized controlled trials. | Clément Chollat Stéphane Marret | 2018 | Neural Regeneration Research2018，13，12： | 5 |
| 2 | prevention of cere- bral palsy using magnesium sulte in pre-term newborns 显示文摘 | Marret S Chollat C Leveque C | 2011 | Arch Pediatr2011，18，3： | 1 |
| 3 | Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor(erythroid-derived 2)-like 2 pathway显示文摘 | Scannevin RH Chollate S Jung MY | 2012 | J Pharmacol Exp Ther2012，341，1： | 1 |
| 4 | Fumarates pro- mote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway 显示文摘 | Scannevin RH Chollate S Jung MY | 2012 | Pharmacol Exp Ther2012，341，： | 1 |
| 5 | Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway显示文摘 | Scannevin R H Chollate S Jung M | | 0，，01： | 1 |
| 6 | Fumarates promote cytoprotection of central nervous system cells against oxi- dative stress via the nuclear factor ( erythroid - derived 2 ) - like 2 pathway显示文摘 | SCANNEVIN R H CHOLLATE S JUNG M Y | 2012 | J Pharmacol Exp Ther2012，341，1： | 1 |
| 7 | Fumarates promote cytoprotection of central nervous system cells a- gainst oxidative stress via the nuclear factor (erythroid- derived 2) -like 2 pathway 显示文摘 | Scannevin R H Chollate S Jung M Y | 2012 | J Pharmacol Exp Ther2012，341，1： | 1 |
| 8 | Fumarates promote cyto-protection of central nervous system cells against oxidative stress via the Nrf2 pathway显示文摘 | Scannevin RH Chollate S Jung MY | 2012 | J Pharmacol Exp Ther2012，341，1： | 1 |
| 9 | Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial显示文摘 | Ka Sing Lawrence Wong Christopher Chen Jianhui Fu Hui Meng Chang Nijasri C Suwanwela Yining N Huang Zhao Han Kay Sin Tan Disya Ratanakorn Pavithra Chollate Yudong Zhao Angeline Koh Qing Hao Hugh S Markus | 2010 | Lancet Neurology2010，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员